Alejandra Guillermina Miranda-DĂ­az | Clinical Research | Women Researcher Award

Posted on by sciencefather

Prof. Dr. Alejandra Guillermina Miranda-DĂ­az | Clinical Research | Women Researcher Award

Alejandra Guillermina Miranda DĂ­az is a distinguished Professor and Researcher with extensive experience in the fields of general surgery, pharmacology, and clinical research. Having pursued a lifelong passion for surgery, she became a Medical Surgeon and Partero at the University of Guadalajara, later specializing in General Surgery and obtaining a Master’s in Medical Sciences and a Doctorate in Pharmacology. Her academic journey reflects a commitment to advancing medical research, particularly in inflammatory diseases and oxidative stress. Miranda DĂ­az has held significant roles in academia, such as coordinating master’s programs in Medical Sciences and mentoring numerous graduate students. Her expertise has led to collaborations with hospitals and medical professionals on various groundbreaking studies. Her research focuses on understanding the mechanisms of inflammation and oxidative stress, contributing significantly to advancements in clinical pharmacology and surgical practice.

Profile

Education 

Alejandra Guillermina Miranda Díaz’s educational background is rich and diverse, rooted in the University of Guadalajara. She began her academic journey with a Bachelor’s degree in Medicine (1971–1977), followed by an advanced specialization in General Surgery (1983). Driven by a deep interest in medical research, she pursued a Master’s in Medical Sciences (1992), and later, a Doctorate in Pharmacology (2003), solidifying her status as an expert in the field. These academic milestones, supported by a strong foundation in clinical surgery, enabled her to bridge the gap between practical medical procedures and theoretical scientific exploration. Throughout her career, she has been dedicated to applying her educational experience to improve medical knowledge, train future professionals, and contribute to groundbreaking research in fields such as inflammation, oxidative stress, and pharmacology.

Experience 

Alejandra Guillermina Miranda Díaz has dedicated over 40 years to both clinical practice and academic instruction. She began her career as a General Surgeon in the IMSS (Mexican Social Security Institute) in 1983, advancing through various leadership roles such as the Coordinator of the Laparoscopic Surgery Program and Sub-Director of the Medical Morning Shift at Hospital General Regional No. 45. In 2001, she transitioned to academia, becoming a Professor and Researcher in the Department of Physiology at the University of Guadalajara’s Center for Health Sciences. Her role as the Coordinator for various Master’s and Doctorate programs in Medical Sciences allowed her to shape the careers of numerous students. Her expertise has earned her a prominent place in the field, with notable distinctions such as membership in multiple medical associations and the System of National Researchers (SNI), where she holds the level II status until 2026.

Research Focus 

Alejandra Guillermina Miranda Díaz’s research primarily focuses on the role of inflammation and oxidative stress in various diseases, particularly in nephrology and metabolic disorders. Her research examines the complex mechanisms of these processes in conditions such as lupus nephritis, diabetes, and obesity. By studying toll-like receptors (TLRs) such as TLR7 and TLR9, Miranda Díaz explores how these receptors influence disease progression and contribute to inflammatory responses. Her work is pivotal in understanding the broader implications of oxidative stress and inflammation, offering potential therapeutic targets for chronic diseases. Currently, her research includes investigating how inflammation and oxidative stress affect renal function in lupus nephritis and exploring their potential links to metabolic syndrome and obesity. Her work fosters collaboration between medical institutions and researchers, aiming to improve patient care and medical treatment strategies through evidence-based scientific discoveries.

Publication Top Notes

  • The Role of TLRs in Obesity and Its Related Metabolic Disorders 🧬
  • The Expression of Toll-like Receptors (TLR7 and TLR9) in Class III and Class IV of Recently Diagnosed Lupus Nephritis with 12-Month Follow-Up 🧪
  • The Sigma-1 Receptor Exacerbates Cardiac Dysfunction Induced by Obstructive Nephropathy: A Role for Sexual Dimorphism 💖
  • Clinical Impact Using Low Dose Mycophenolate Mofetil with Tacrolimus on Acute Rejection, Infectious Diseases, and Non-Infectious Complications in Renal Transplant: A Single Hospital Experience in Mexico 🏥
  • The Effect of Enalapril, Losartan, or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients 🌱
  • Foods with Potential Prooxidant and Antioxidant Effects Involved in Parkinson’s Disease 🧠
  • The Role of Oxidative Stress in Physiopathology and Pharmacological Treatment with Pro- and Antioxidant Properties in Chronic Diseases ⚖️
  • The Effect of Visceral Abdominal Fat Volume on Oxidative Stress and Proinflammatory Cytokines in Subjects with Normal Weight, Overweight, and Obesity 🏃‍♀️

 

 

Wijdan Al-Ahmadi | Biomedicine | Best Researcher Award

Posted on by sciencefatherLeave a Comment on Wijdan Al-Ahmadi | Biomedicine | Best Researcher Award

Dr. Wijdan Al-Ahmadi | Biomedicine | Best Researcher Award

Associate scientest, King Faisal specialist hospital and research center, Saudi Arabia

Dr. Wijdan Al-Ahmadi is a seasoned researcher with over 20 years of experience in biomedicine, focusing on cancer biology, immunology, and disease mechanisms. Based in Riyadh, Saudi Arabia, she is a key member of the Molecular Biomedicine Research Department at King Faisal Specialist Hospital and Research Center. Her work spans diverse fields, including inflammatory diseases and cardiovascular research. Notably, in 2023, she contributed to a groundbreaking experiment aboard the International Space Station (ISS), highlighting her ability to conduct research in extreme environments. Dr. Al-Ahmadi has demonstrated leadership through her work as an educator, mentoring students at various academic levels. Her contributions continue to push the boundaries of biomedicine, paving the way for new therapeutic strategies and personalized medicine approaches.

Profile

Education

Dr. Wijdan Al-Ahmadi holds a Ph.D. in Bioscience from Cardiff University (2015–2019), where she focused on cancer and immunology research. She also earned a B.Sc. in Biochemistry from King Saud University (1994–1998). Her academic journey has equipped her with advanced expertise in molecular biology, cancer research, and biomedical sciences. Dr. Al-Ahmadi’s educational foundation is complemented by her extensive hands-on experience in laboratory settings, which has enabled her to contribute to numerous pioneering studies. Through her formal education and continuous professional development, she has maintained a passion for unraveling disease mechanisms and enhancing health outcomes through scientific innovation.

Experience

Dr. Al-Ahmadi’s career spans over two decades in the field of biomedicine. She currently serves as an Associate Scientist at King Faisal Specialist Hospital and Research Center in Riyadh, where she leads advanced research projects in cancer biology and immunology. Prior to this, she was a Post-doctoral Fellow (2020–2023), focusing on cancer and inflammatory disease mechanisms. Dr. Al-Ahmadi’s experience includes roles as a Research Assistant (2007–2015) and a Research Technician (2002–2006), where she was deeply involved in cancer research and molecular biology assays. She has also mentored Ph.D., master’s, and undergraduate students throughout her career. Her research has had significant impact both in clinical settings and in experimental fields, including innovative studies aboard the ISS in 2023, demonstrating her versatility in different research environments.

Research Focus

Dr. Wijdan Al-Ahmadi’s research is focused on understanding the underlying mechanisms of diseases, particularly cancer, inflammatory disorders, and cardiovascular diseases. She is dedicated to uncovering how specific genetic mutations and signaling pathways contribute to disease progression, aiming to identify novel therapeutic targets for better patient outcomes. Dr. Al-Ahmadi’s work in space science is also notable, having contributed to microgravity research aboard the ISS, exploring how human physiology and disease processes respond in space. Her findings not only have applications for space health but also provide critical insights that can benefit human health on Earth. She is driven by the potential of personalized medicine and therapeutic interventions that address the root causes of disease.

Publication Top Notes

  1. Pro-atherogenic actions of signal transducer and activator of transcription 1 serine 727 phosphorylation in LDL receptor deficient mice via modulation of plaque inflammation. 🧬🔬
  2. Protective effects of a unique combination of nutritionally active ingredients on risk factors and gene expression associated with atherosclerosis in C57BL/6J mice fed a high-fat diet. 🥗🧪
  3. Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells. 🧑‍🔬🦠
  4. miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. 🧬💡
  5. The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes. 🔬💥
  6. Alternative polyadenylation variants of the RNA binding protein, HuR: abundance, role of AU-rich elements and auto-Regulation. 🧬📊
  7. Cloning-free regulated monitoring of reporter and gene expression. 🧬🧑‍🔬
  8. RNase L downmodulation of the RNA-binding protein, HuR, and cellular growth. 🔬🧑‍🔬
  9. Bioinformatics and experimental derivation of an efficient hybrid 3′ untranslated region and use in expression active linear DNA with minimum poly(A) region. 💻🧬
  10. Expedient liquid chromatographic method with fluorescence detection for montelukast sodium in micro-samples of plasma. 🧪💉

 

 

 

Jorge Amador Berlanga-Acosta | Medicine and Health Sciences | Best Researcher Award

Posted on by sciencefatherLeave a Comment on Jorge Amador Berlanga-Acosta | Medicine and Health Sciences | Best Researcher Award

Prof Dr Jorge Amador Berlanga-Acosta | Medicine and Health Sciences | Best Researcher Award

Research project leader, Center for Genetic Engineering and Biotechnology, Cuba

Dr. Jorge Amador Berlanga Acosta is a distinguished Cuban veterinary medicine and pharmaceutical scientist, born on October 11, 1962, in Bayamo, Granma, Cuba. With a career spanning over three decades, he specializes in the pharmacological applications of Epidermal Growth Factor (EGF) for wound healing and diabetic foot ulcers. He holds several prestigious titles, including Member of Honor of the Cuban National Academy of Science and Distinguished Professor at the University of Electronic Science and Technology of China. Dr. Berlanga has made significant contributions to biomedical research and has been instrumental in various clinical trials and technical missions across multiple continents, earning recognition for his impactful work in regenerative medicine and pharmacology. His expertise is complemented by a strong commitment to education and mentorship in the scientific community. 🌟

Profile

Google Scholar

Strengths for the Award

  1. Extensive Education and Training: Dr. Berlanga has a solid academic background with a Doctor of Veterinary Medicine and a Ph.D. in Pharmaceutical Sciences and Pharmacology. His post-doctoral fellowships at prestigious institutions like the University of Alberta and Imperial Cancer Research Fund highlight his commitment to advancing medical knowledge.
  2. Research Contributions: His extensive work on epidermal growth factor (EGF) and its applications in wound healing, particularly in diabetic foot ulcers, is groundbreaking. He has led numerous research projects and has a substantial number of publications in reputable journals, indicating his active engagement in critical biomedical research.
  3. Recognition and Awards: Dr. Berlanga has received numerous prestigious awards, including the “HĂŠroe del Trabajo de la RepĂşblica de Cuba” and various international recognitions, showcasing his impact and contributions to the field.
  4. Leadership in Scientific Community: His roles in coordinating research commissions, leading projects, and serving as a speaker at over 40 international conferences illustrate his leadership and influence in the scientific community.
  5. Multidisciplinary Approach: His research spans various aspects of pharmacology, tissue repair, and regenerative medicine, demonstrating his ability to integrate knowledge across disciplines effectively.
  6. International Collaboration: Dr. Berlanga’s involvement in international workshops and conferences shows his commitment to collaboration and the dissemination of knowledge globally.

Areas for Improvement

  1. Broader Research Scope: While Dr. Berlanga’s focus on EGF is significant, exploring additional areas of research could enhance his impact. Diversifying his research portfolio may lead to novel insights and applications in other fields of medicine.
  2. Public Engagement and Communication: Increasing his outreach efforts to communicate research findings to the general public could enhance the visibility of his work and its implications for healthcare.
  3. Mentorship Opportunities: Engaging more with younger researchers and students through mentorship programs could foster the next generation of scientists and broaden the research community’s perspectives.
  4. Interdisciplinary Collaboration: Further collaboration with other scientific disciplines, such as engineering or technology, could lead to innovative approaches in his research areas.

Education

Dr. Berlanga’s educational journey began with primary education in Bayamo, Granma, followed by secondary schooling. He obtained his Doctor of Veterinary Medicine from the Universidad de Granma in 1985. He furthered his studies with a PhD in Pharmaceutical Sciences and Pharmacology from the Universidad de La Habana in 2000. His academic pursuits included post-doctoral fellowships at renowned institutions, such as the University of Alberta in Canada and the Leicester General Hospital in the UK, focusing on wound healing and gastroenterology. Additionally, he completed numerous specialization courses in clinical pathology, molecular biology, and experimental pharmacology. His diverse educational background has equipped him with the knowledge and skills to advance biomedical research and contribute to the field significantly. 🎓

Experience

Dr. Berlanga’s professional experience includes roles as an instructor and assistant lecturer in Anatomical Pathology at the Universidad de Granma and as an Associate Professor of Pathology. He has been a researcher at the Centro de IngenierĂ­a GenĂŠtica y BiotecnologĂ­a (CIGB) in Havana, focusing on EGF’s pharmacological effects and wound healing mechanisms. Over the years, he has led various departments and projects within CIGB, including preclinical studies and diabetic foot ulcer healing initiatives. His leadership has driven significant advancements in understanding tissue repair and regeneration. In addition to his research, Dr. Berlanga has been a prominent speaker at numerous international conferences, sharing his findings and fostering collaboration in the scientific community. His extensive experience has established him as a leading figure in the field of biomedical sciences. 🔬

Awards and Honors

Dr. Berlanga’s contributions to science have earned him numerous accolades. He received the Alberta Heritage Foundation Scholarship in 1995 and the Royal Society Annual Award in 1998. In 2011, he was honored with the DistinciĂłn Carlos J. Finlay and recognized by the World Intellectual Property Organization as the best young inventor. His achievements include being named Hijo Ilustre de Granma and Bayamo, as well as receiving the prestigious title of HĂŠroe del Trabajo de la RepĂşblica de Cuba in 2020. He has also been acknowledged as a Distinguished Professor at the University of Electronic Science and Technology of China. These awards highlight his significant impact on science and society through innovative research and dedication to education. 🏆

Research Focus

Dr. Berlanga’s research primarily focuses on the pharmacological applications of Epidermal Growth Factor (EGF) in wound healing and tissue regeneration. His investigations have led to the development of various animal models to study EGF’s effects on diabetic foot ulcers, ischemia/reperfusion injury, and gastrointestinal health. He explores the molecular mechanisms underlying EGF’s protective properties and its role in enhancing healing processes. His work also includes studying cellular pathologic memory and its implications in diabetes and wound chronicity. Dr. Berlanga’s commitment to advancing regenerative medicine continues to shape therapeutic strategies for complex wound healing challenges, making significant contributions to biomedical science. 🧬

Publication Top Notes

  • Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis
  • The pro‐inflammatory environment in recalcitrant diabetic foot wounds
  • Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo …
  • Epidermal growth factor in clinical practice–a review of its biological actions, clinical indications and safety implications
  • Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure
  • Intralesional injections of Citoprot‐PÂŽ (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation
  • Glucose toxic effects on granulation tissue productive cells: the diabetics’ impaired healing
  • Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds
  • Diabetic foot ulcers and epidermal growth factor: revisiting the local delivery route for a successful outcome
  • Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats
  • Diabetic lower extremity wounds: the rationale for growth factors‐based infiltration treatment
  • Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction
  • Cellular senescence as the pathogenic hub of diabetes-related wound chronicity
  • Wound chronicity, impaired immunity and infection in diabetic patients
  • Insulin resistance at the crossroad of Alzheimer disease pathology: A review
  • Potency and stability of C terminal truncated human epidermal growth factor
  • Systemic translation of locally infiltrated epidermal growth factor in diabetic lower extremity wounds
  • Epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) as tissue healing agents: clarifying concerns about their possible role in malignant transformation and …
  • Intestinal growth in parenterally‐fed rats induced by the combined effects of glucagon‐like peptide 2 and epidermal growth factor
  • Medical practice confirms clinical trial results of the use of intralesional human recombinant epidermal growth factor in advanced diabetic foot ulcers

Conclusion

Dr. Jorge Amador Berlanga Acosta exemplifies the qualities of an outstanding researcher through his extensive educational background, significant contributions to science, and recognized leadership. His innovative work on EGF and wound healing positions him as a strong candidate for the Best Researcher Award. By broadening his research scope, enhancing public engagement, and fostering mentorship, he can further elevate his impact on the scientific community and society at large.